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Summary 
Here, we describe proof of concept of a novel method for delivering volatile anaesthetics, where the liquid anaesthetic 
(sevoﬂurane or isoﬂurane) is formulated into an emulsion that is contained in a compact, lightweight device through 
which carrier gas ﬂows. Release of anaesthetic is achieved by stirring of the formulation, allowing controlled and 
responsive release of anaesthetic at a variety of ﬁxed ﬂow rates between 0.5 l.min-1  and 5 l.min-1,  with ventilated, 
non-ventilated and draw-over breathing systems. Anaesthetic release was evaluated using target anaesthetic concen- 
trations ranging from 0.5% v/v to 8% v/v to mimic those typically required for induction and maintenance of anaes- 
thesia, and lower concentrations suitable for sedation. Under all conditions, output could be maintained within 0.1% 
v/v of the intended setting, and the device could deliver a controlled level of anaesthetic for at least 60 min, with 
compensation for different ambient temperatures (10–30 °C) and carrier gas ﬂow rates. This device offers a simple, 
inexpensive method of delivering safe concentrations of volatile anaesthetics for a wide range of applications. 
 
 
 
Introduction 
There are two basic types of vaporisers: plenum  and 
draw-over [1]. The plenum vaporiser has a high resis- 
tance to gas ﬂow and is placed ‘out of circuit’, typically 
on the back-bar of an anaesthetic machine. In contrast, 
draw-over vaporisers are placed in the breathing sys- 
tem. They have a lower resistance to gas ﬂow, making 
them suitable for use with spontaneously breathing 
patients. Other methods of vapourising volatile anaes- 
thetic  agents  include  using  an  injector  system,  for 
example, in the Flow-i anaesthetic machine (Maquet 
Cardiovascular LLC, Wayne, NJ,  USA), or the DIVA 
cassette used by the Zeus anaesthesia machine (Drager, 
Lu€beck, Germany). Alternatively, the liquid anaesthetic 
can be vapourised close to the patient, as in the Ana- 
ConDa device [2]. 
Vaporisers classically used by anaesthetists are not 
without clinical problems. During the 1988–1996 per- 
iod, 16 incidents were reported in the United Kingdom 
to  the  Medical Devices Agency (MDA), where leaky 
  
 
vaporiser  back-bar  connections  led  to  patient 
awareness during surgery [3]. Adverse incidents associ- 
ated with anaesthetic vaporisers were also reported to 
the Manufacturer and User Facility Device Experience 
Database  (MAUDE)  operated  by  the  US  Food  and 
Drug Administration [4]; eight separate reports involv- 
ing vaporisers were logged in the nine months from 1 
January to 30 September, 2013. In  addition, some of 
the equipment required to deliver volatile anaesthetics 
to patients is extremely expensive and complex. 
These issues led this group to consider alternative 
methods of delivery for volatile agents, seeking a com- 
pact, portable and simple-to-use delivery device that 
would have the potential to broaden access to safe 
anaesthesia in challenging situations such as ﬁeld 
anaesthesia and the developing world. Hence, a simple 
solution with low-power requirement and the potential 
to be battery-driven was required. It was hypothesised 
that formulating the anaesthetic as an oil-in-water 
emulsion would reduce the rate of evaporation by 
restricting transport of anaesthetic to the surface of the 
liquid [5]. This could reduce the concentration of 
anaesthetic vapour in the headspace of a chamber con- 
taining the emulsion. Hence, the formulation would 
provide a mechanism for controlled release of anaes- 
thetic into a carrier gas stream, forming the basis of a 
device for delivery of volatile anaesthetics. 
Such a device may also have a number of novel fea- 
tures that could make administration of anaesthetics 
safer. There are inherent limitations in the concentra- 
tion of vapour that can be delivered from a speciﬁcally 
formulated emulsion. Also, if agitation of the emulsion 
resulted in the production of predictable vapour concen- 
tration, this would for the ﬁrst time introduce the poten- 
tial for simple feedback control mechanisms of vapour 
concentration. Replacing the ‘traditional’ design of large 
metal heat-sink and control of gas ﬂow with a simple, 
light and potentially disposable device would introduce 
new opportunities for portability and cost reduction. 
Here, we describe a novel device containing an 
emulsion of the volatile anaesthetic agent. The device 
is intended to be connected to the fresh gas ﬂow inlet 
of a circle, Bain or Magill breathing system. Drug 
delivery is designed to  be controlled by stirring rate. 
However, for experimental completeness, performance 
was tested at a range of ﬂow rates. For this proof of 
concept study, the performance of a single formulation 
was tested over a range of temperatures from 10 °C to 
30 °C and  gas ﬂows of 0.5 to  5 l.min-1,  with target 
anaesthetic release concentrations of between 0.5 and 
8% v/v. It was decided to examine the delivery of both 
sevoﬂurane  and  isoﬂurane,  as  these  are  two  of  the 
most commonly used volatile agents, and have boiling 
points  that  are  easily managed  within  the  proposed 
drug delivery system. For this reason, we avoided test- 
ing desﬂurane due to its low boiling point. 
 
Methods 
Research Ethics Committee approval was not required 
for this laboratory-based study. 
Reagent-grade water was produced by a RiOs 5 
puriﬁcation  system  (Millipore,  Billerica, MA,  USA). 
The ﬂuorinated surfactant Zonyl FSN-100 (technical 
grade, ABCR, Karlsruhe, Germany)  was used as 
received. Zonyl FSN-100 is a commercial non-ionic 
surfactant  of  the  perﬂuoroalkylpolyoxyethylene type 
with  an  average  chemical  structure  of  F(CF2CF2)3- 
8CH2CH2O(CH2CH2O)10-15H  [6, 7]. Two anaesthetic 
agents, sevoﬂurane (99.98% purity; Abbott, Maiden- 
head, UK) and isoﬂurane (99.9% purity; Nicholas Pira- 
mal, London, UK) were used as received. 
Formulations of sevoﬂurane and isoﬂurane were 
prepared by vigorously shaking (by hand) a known 
volume of the anaesthetic with a pre-prepared aqueous 
surfactant solution for a ﬁxed time of 60 s. Formula- 
tion compositions were 50 ml sevoﬂurane with 90 ml 
of aqueous Zonyl FSN-100 solution (20 w/w %), and 
30 ml  isoﬂurane  with  110 ml  of  an  aqueous  Zonyl 
FSN-100 solution (30 w/w %). All formulations were 
prepared in a 500ml DURAN laboratory bottle with a 
screw cap, and  were thermally equilibrated at  20 °C 
before testing. 
The  prepared   emulsions  were  characterised  by 
light microscope imaging using an Olympus BX50 sys- 
tem microscope (Olympus, London, UK), ﬁtted with 
JVC TK-C1380 colour video camera (JVC, Yokohama, 
Japan) and analysed using Image J software (Fiji, avail- 
able   at   http://ﬁji.sc/Fiji).  Additional   measurements 
were obtained from dynamic light-scattering measure- 
ments using a Brookhaven ZetaPlus analyser (Broo- 
khaven Instruments  Ltd., Holtsville, NY, USA). For 
light-scattering   measurements,   the   emulsions   were 
  
 
diluted by a factor of 20–50 depending on the emul- 
sion concentration. Gas chromatography–mass spec- 
tometry  (GC–MS)  analyses  were  carried  out  on  a 
Waters GCT Premier instrument (Waters Corporation, 
Milford, MA, USA) to determine both the amount  of 
anaesthetic gas in the gas space above the formulation 
and whether any of the excipients were identiﬁable in 
this gas phase. 
The controlled release of anaesthetic agents from 
the formulations was tested and delivered using the 
experimental setup shown in Fig. 1a. The anaesthetic 
delivery device is comprised of two main parts. The ﬁrst 
part is the cartridge, which contains the formulation and 
is where evaporation of the  anaesthetic agent occurs. 
The cartridge comprises a 250-ml cylindrical plastic 
chamber plugged into a Teﬂon ﬁtting (the ﬂow module) 
with  standard   22-mm   inlet  and   outlet  connectors 
(Fig. 1a). The second part is a magnetic stirrer which 
controls the stirring rate of the formulation through a 
magnetic bar placed inside the chamber. A demonstra- 
tor device is shown in Fig. 1b; however, for this proof of 
concept work a commercial stirrer was used (MR 3002; 
Heidolph UK, Saffron Walden, UK) in tandem with the 
cartridge. Changing the rate of stirring alters the rate of 
evaporation of the anaesthetic and hence the concentra- 
tion of anaesthetic delivered from the device. 
The ﬂow required  will range from  150 ml.min-1 
(basal oxygen consumption in a closed circuit system) 
to a minimum  of 4 l.min-1   when used with a semi- 
closed breathing system such as the Bain or Magill. As 
ﬂow of gas through the chamber changes, the concen- 
tration of the volatile anaesthetic will also vary. How- 
ever, as the anaesthetic delivery device is intended to 
be placed between the fresh gas source and the breath- 
ing system, ﬂow through  the device will remain con- 
stant once set by the user. Initial testing was, therefore, 
performed at a ﬁxed ﬂow rate of 1 l.min-1,  with fur- 
ther   testing  at  both  higher  (4 l.min-1)   and  lower 
(0.5 l.min-1) ﬂows. 
Concentration of the anaesthetic agent in the out- 
let ﬂow was measured with an anaesthetic monitor 
(Capnomac Ultima; Datex Instrumentarium  Inc., Hes- 
linki, Finland), calibrated according to the manufac- 
turer’s  instructions immediately before the start of the 
study. The Capnomac records the anaesthetic gas con- 
centration   (in   volume   percent)   every  10 s,   to   a 
(a) 
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Figure 1 The anaesthetic delivery device. (a) Sche- 
matic representation of the device (not to scale). (b) 
Photograph of the demonstrator device. The inlet con- 
nector is connected to the gas supply and the outlet 
connector is connected to an anaesthetic monitor. 
 
precision of 0.01%. A serial port  connection to a PC 
was used to record data for subsequent analysis. 
The stirring rate of the magnet was varied to 
determine  its effect on  the  output  of the  anaesthetic 
delivery device. The stirring rate was then used to deli- 
ver particular different concentrations of sevoﬂurane at 
room  temperature  (20 °C). Stirring was also used to 
compensate for changes in sevoﬂurane release caused 
  
 
by working at (i) different ambient temperatures, and 
(ii) different gas ﬂows. 
The concentration of the volatile anaesthetic 
released from the emulsion was measured over a tem- 
perature range from 10 °C to 30 °C to allow for varia- 
tions in ambient temperatures. For temperatures other 
than  room  temperature  (20 °C),  the  temperature  of 
the ﬂow module was controlled using a double-walled 
glass  water  jacket  connected  to  a  circulating  water 
bath. Changes in the temperature of the emulsion dur- 
ing evaporation were monitored using a digital ther- 
mometer (KM 3013; Kane-May Ltd., Welwyn Garden 
City, UK) with a thermocouple placed inside the emul- 
sion. Repeat experiments were performed to ensure 
reproducibility of the  formulation  and  device output. 
In all cases, the levels of anaesthetic released were able 
to be reproduced to within ±0.2%  v/v. Example data 
are given in the results section. 
In  order  to  demonstrate  the  possibility of using 
the device with volatile anaesthetics other than sevoﬂu- 
rane, an emulsion was also formulated with isoﬂurane. 
This was tested at 1 l.min-1  carrier gas ﬂow with stir- 
ring rate adjusted to maintain target concentrations of 
1.2 and 2.3% v/v, which corresponds to approximately 
1 and 2 minimum alveolar concentration (MAC), 
respectively, in the carrier gas. 
Breathing system test rigs were set up as shown in 
Fig. 2, using Mapleson A (Fig. 2a), circle (Fig. 2b) and 
draw-over (Fig. 2c) systems for spontaneous breathing 
and  a co-axial Mapleson D system for positive pres- 
sure ventilation (Fig. 2d). An artiﬁcial lung (Vent Aid 
TTL Model 1600 Training Test Lung; Michigan Instru- 
ments, Grand Rapids, MI, USA) was used to test the 
anaesthetic breathing systems in all conﬁgurations. 
 
Results 
Characterisation of the formulation by microscopy 
conﬁrmed the presence of discrete droplets (Fig. S1), 
typically 5 lm or less in diameter; that is, a dispersion 
or ‘nano-emulsion’ structure. The formulation was 
optimised to ensure that no separation of the neat 
anaesthetic occurred over a timescale signiﬁcantly 
greater than the experiment (> 12 h). It is also worth 
noting that a single formulation was used to obtain 
release at the full range of gas ﬂows and target concen- 
trations  studied. This  represents  an  improvement  on 
formulations identiﬁed previously, where different for- 
mulations were used for individual target concentra- 
tions [8]. 
If  dried  carrier  gas  is  used  during  anaesthetic 
release, some evaporation of water occurs (< 5% over 
90 min), but this has no effect on formulation stability, 
and  substantial dilution  of the  evaporated water into 
the carrier gas ensured that no water droplets were 
formed in the breathing circuit tubing. Where the car- 
rier  gas  was  pre-humidiﬁed  by  bubbling  through  a 
water trap, no measureable loss of water from the for- 
mulation was observed during release testing. 
At a ﬁxed gas ﬂow rate and constant stirring rate, 
the level of anaesthetic release from a given formulation 
drops gradually over time as the amount of sevoﬂurane 
remaining in the formulation decreases (Fig. S2), con- 
sistent with the proposed evaporation mechanism [8]. 
By altering stirring rate, the output  of the anaesthetic 
delivery device can be made to vary in a responsive and 
predictable manner  (Fig. 3). It was, therefore, possible 
to  deliver clinically relevant  target  concentrations  of 
sevoﬂurane (Fig. 4a–c), which could be maintained for 
at least 90 min by periodically adjusting the stirring rate 
to compensate for the drift observed otherwise. Hence, 
a target value could be maintained with minimal varia- 
tion (well within the required regulatory tolerance) of 
the  measured  concentrations.  These  data  could  be 
reproduced   at   the   different   ﬂow  rates:  1 l.min-1 
(Fig. 4a); 4 l.min-1  (Fig. 4b); and 0.5 l.min-1  (Fig. 4c) 
tested in this preliminary study. The consequences of 
stirring failure were also studied (Fig. S3). 
Despite the relatively simple method  of emulsion 
preparation, the results obtained were reproducible to 
within regulatory tolerance. Example data to demon- 
strate this are shown in Fig. S4. Good reproducibility 
was also obtained on recycling the emulsion by ‘top- 
ping-up’ the anaesthetic content (Fig. S5), although 
regulatory requirements  would prohibit  this approach 
in practice. Headspace analysis by GC–MS was carried 
out to conﬁrm that only sevoﬂurane was released from 
the formulation. No surfactant was detected in the 
volatile phase to the detection limit of the instrument 
used (Fig. S6). 
For a given formulation, the time for which the 
release is maintained is dependent primarily on the 
amount   of  formulation   and,   therefore,  anaesthetic 
  
 
(a) Monitor 
 
Fresh 
gas flow 
 
Lung 
simulator 
 
 
 
 
(b) 
Fresh 
gas flow 
Monitor  
 
 
Lung 
simulator 
 
 
(c) Monitor 
 
 
Lung 
simulator 
 
 
 
(d) Monitor 
 
Fresh 
gas flow 
 
 
 
Ventilator 
 
Lung 
simulator 
 
 
Figure 2 Test rigs used. For spontaneous breathing, Mapleson A (a), circle (b) and draw-over (c); for ventilation, 
co-axial Mapleson D (d). 
 
present. At higher ﬂow rates and higher target anaes- 
thetic concentration, for example, 4% v/v and 2% v/v 
at 4 l.min-1  (Fig. 4b), the time for which a given vol- 
ume of formulation will deliver the desired output  is 
shorter than at lower ﬂows and/or concentrations (data 
acquisition has been halted at a maximum of 90 min). 
Where longer timescales are required, the cartridge- 
based design of the device means that  a fresh anaes- 
thetic cartridge can be easily installed. 
Controlled  anaesthetic  release could  also  be 
obtained  using  emulsiﬁed  isoﬂurane,  indicating  that 
the formulation-based mechanism of vapour release 
translates to other volatile anaesthetics (Fig. 5). 
As shown in Fig. 6a, for a given stirring rate, the 
ambient  temperature  has  an  effect on  the  output  of 
the delivery device, with a higher measured anaesthetic 
concentration observed at higher ambient temperatures 
(as expected). However, these effects were easily coun- 
terbalanced by adjusting the stirring rate to obtain the 
target output independent of the ambient temperature. 
  
The effect of carrier gas ﬂow rate at constant stir- 
ring rate was also investigated (Fig. 6b). As anticipated, 
as ﬂow rate increases, dilution of the evaporating 
anaesthetic causes a drop in the measured sevoﬂurane 
concentration. However, by adjusting the stirring rate 
the measured concentration can be restored to the tar- 
get level. 
When the device was tested using an equivalent 
volume of neat anaesthetic, the observed release levels 
were 9 ± 1% v/v and  7 ± 1% v/v at  1 l.min-1   and 
4 l.min-1   gas ﬂows, respectively (Fig. S7a), indicating 
the  importance  of  the  emulsion  in  retarding  anaes- 
thetic evaporation to clinically useful levels. 
For  neat  anaesthetic  liquid,  signiﬁcant  evapora- 
tion-induced cooling occurs (Fig. S7b). For the formu- 
lation,  however, the  liquid  temperature  remains 
broadly constant during sevoﬂurane evaporation (Fig. 
S7b),  changing   by   only   approximately  2 °C   over 
60 min. This is due to the high speciﬁc heat capacity 
of the aqueous continuous phase of the emulsion. 
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Figure 3 Sevoﬂurane output concentrations of the 
anaesthetic delivery device at various stirring rates with 
an input ﬂow of 1 l.min-1  nitrogen at 20 °C. 
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The dispersion device was also tested with a range 
of clinically-used breathing circuits, using a ventilator 
and/or lung simulator to mimic spontaneously breath- 
ing or ventilated patients. These data show that vapour 
levels required for inhalation induction, as well as main- 
tenance of anaesthesia, could theoretically be obtained 
with this device, and that this could be achieved in the 
same manner (ﬂow and anaesthetic concentration pro- 
ﬁle)  as  with   conventional   vaporiser-based  systems 
(Figs. 7 and  8). Figures 7a and  b show data  using a 
Magill (Mapleson A) breathing circuit with ﬂows set to 
mimic a spontaneously breathing patient (500 ml end- 
tidal  volume, 15 breaths.min-1,  inspired:expired ratio 
1:2), illustrating that high anaesthetic concentrations of 
sevoﬂurane can  be  achieved and  maintained  (up  to 
8% v/v); the target timescale of 10 min (Fig. 7a), and a 
target maintenance value of 2% v/v as maintained over 
an extended time period (Fig. 7b). Figure 8 shows main- 
tenance  data  using  a  co-axial  Mapleson  D  system, 
indicating that  the  formulation  and  device would be 
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suitable  for  a  mechanically  ventilated  patient.  Fig- 
ures 9a–c illustrate function at low fresh gas ﬂow rates 
(1 l.min-1)   used  with  circle  breathing  systems  for 
mechanically ventilated (Figs. 9a and  b)  and  sponta- 
neously breathing (Fig. 9c) patient models, with induc- 
tion (Fig. 9a) and maintenance (Figs. 9b and c) targets 
maintained.  Figure 9d  shows the  equilibration  of the 
breathing system, showing that at a constant 1 l.min-1 
rate, the  target 2% v/v sevoﬂurane is reached within 
10 min. 
  
Figure 4 Output sevoﬂurane concentrations of the 
anaesthetic delivery device for target sevoﬂurane con- 
centrations of 1.0% v/v (circles), 2.1% v/v (squares), 
3.2% v/v (triangles) and 4.0% v/v (diamonds), with an 
input ﬂow of nitrogen at 20 °C with gas ﬂows of (a) 
1 l.min-1  (b) 4 l.min-1  and (c) 0.5 l.min-1. Variation 
from the target output was generally less than 0.1% v/v. 
 
 
Finally, Figs. 10a and b demonstrate that low tar- 
get concentrations suitable for volatile sedation can be 
obtained with the formulation. Target values of 0.5% 
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Figure 5 Output isoﬂurane concentrations of the 
anaesthetic delivery device for target isoﬂurane concen- 
trations of 1.2% v/v (circles) and 2.3% v/v (squares), 
with an input ﬂow of nitrogen of 1 l.min-1  at 20 °C. 
Variation from the target output was generally less 
than 0.1% v/v. 
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v/v, 1% v/v and  1.5% v/v sevoﬂurane were achieved 
and   maintained   using   a   Magill  breathing   circuit 
(Fig. 10a), and in draw-over mode (Fig. 10b). 
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Concentrations of sevoﬂurane and isoﬂurane over a 
range of MAC values (up to 4 MAC) could be deliv- 
ered from a single-emulsion formulation of the volatile 
anaesthetic, with the  level of release at  ﬂows of 0.5– 
4 l.min-1   and over a temperature  range of 10–30 °C, 
 
Figure 6 Sevoﬂurane output concentrations of the 
anaesthetic delivery device (a) at temperatures of 
10 °C (triangles), 20 °C (circles) and 30 °C (squares) 
and ﬁxed ﬂow of 1 l.min-1  and (b) at ﬁxed tempera- 
ture of 20 °C and ﬂow rates of 0.5 l.min- 
controlled by varying the rate at which the formulation and 4 l.min
-
 
1(triangles) 
1  (squares). The stirring rate was ﬁxed 
 
is stirred. Any formulation would be subject to full 
regulatory approval before clinical testing, and the for- 
mulation presented is used to demonstrate proof of 
concept for the dispersion. Other emulsion formula- 
tions containing alternative stabilisers can also be used 
to the same effect, as described in the published patent 
[9]. 
Delivered anaesthetic concentrations are consis- 
tent, predictable and reproducible yet controllable, and 
as such, the  device can  provide an  accurate solution 
for delivering volatile anaesthetics. The power require- 
ments for the stirring are low, so the device could be 
either battery- or mains-powered. 
We have demonstrated  that  the device is suitable 
for use with circle, semi-closed, such as the Bain and 
Magill, or draw-over breathing systems. With all these 
breathing  systems,  vapour  can  be  delivered  reliably 
  
until about 41 min and 46 min, respectively, after 
which stirring rate was altered to provide the same 
output at all three temperatures/both ﬂows. 
 
 
over a wide range of gas ﬂows and concentrations in a 
lighter and more portable device. This portability sug- 
gests potential for delivery of anaesthesia in the ﬁeld, 
pre-hospital care or the developing world, where access 
to  complex equipment  such  as anaesthetic machines 
may be limited and portability is a major advantage. 
Frequently, draw-over vaporisers such as the Oxford 
Miniature Vaporizer and the Diamedica Draw-Over 
Vaporizer [10] are used in these situations. However, 
the ﬂow through this type of vaporiser, and hence the 
concentration  of the  anaesthetic delivered, varies 
widely throughout the respiratory cycle, and limits pre- 
cision of the vaporiser. This new device can deliver 
predictable  concentrations   of  vapour   with  a   wide 
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Figure 8 Sevoﬂurane output of the anaesthetic delivery 
device at 20 °C with a Bain (Mapleson D) breathing 2 
circuit mimicking a patients whose lungs are mechani-
 
 
1.5 cally ventilated (fresh gas ﬂow 5 l.min-1 oxygen, end- 
 
 
1 
 
0.5 
tidal volume 500 ml, 15 breaths.min-1, inhaled:exhaled 
phase time ratio 1:2) target sevoﬂurane concentration 
2% v/v for 60 min. Data shown are an average over 
three runs. Error bars indicate SD. 
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Figure 7 Sevoﬂurane output of the anaesthetic delivery 
device at 20 °C with a Magill (Mapleson A) breathing 
circuit mimicking a spontaneously breathing patient 
(end-tidal volume 500 ml, 15 breaths.min-1, inhaled: 
exhaled phase time ratio 1:2 (a) fresh gas ﬂow 
6 l.min-1  oxygen, target sevoﬂurane concentration 8% 
v/v for 10 min; (b) fresh gas ﬂow 5 l.min-1  nitrogen, 
target value 2% v/v for 60 min. Data shown are an 
average over three runs. Error bars indicate SD. 
 
variety of gas ﬂows, using either pressurised gas or 
inspiratory effort to generate these ﬂows, and is, there- 
fore, as ﬂexible and at least as accurate as the Diamed- 
ica  and  the  Oxford  Minature  draw-over  vaporisers 
when used in similar situations. 
In lower concentrations, anaesthetic vapours such 
as sevoﬂurane may be usefully used for sedation [11]. 
The new device is able to deliver such concentrations, 
which raises the possibility of using this technology to 
develop dedicated sedation devices that  may be used 
in all the situations where draw-over vaporisers can be 
used. The emulsion formulation could be adjusted to 
limit  the  output  concentration,  making  sedation, but 
not anaesthesia, possible. Potentially, such a device 
could   be   safe  for   use   by   non-anaesthetists,   and 
expands the  potential market  for anaesthetic vapours 
  
outside  operating  theatres  if  gas  scavenging can  be 
appropriately managed in these areas. 
The method of using stirring rate to alter delivered 
anaesthetic concentration  also offers the possibility of 
using a feedback mechanism for delivery of anaesthetic 
vapour.  Anaesthetic concentration  may  be  measured 
and the stirring rate adjusted in a single device to pro- 
duce stable concentrations in a wide range of ambient 
temperatures. Unlike vaporisers that use pure sevoﬂu- 
rane, the emulsion formulation limits the amount of 
anaesthetic vapour that can be delivered to the patient 
in the event of equipment failure, adding an extra ele- 
ment of patient safety. 
It seems unlikely that the new device would replace 
conventional vapourisers for intra-operative use in the 
short term because of the long-term investment of man- 
ufacturers in the workstation model that is built around 
conventional anaesthetic machines and plenum 
vapourisers. These require the high-pressure gas source 
delivered by the anaesthetic machine, and the lack of 
portability of the whole system limits the potential use 
of anaesthetic vapours for anaesthesia and sedation out- 
side operating theatres. However, the portability of the 
new device, the limitations in attainable vapour concen- 
tration that can be imposed by tailoring the emulsion 
formulation and the potential to include a feedback loop 
to control anaesthetic concentration offers potential for 
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Figure 9 Sevoﬂurane output of the anaesthetic delivery device at 20 °C with a circle breathing circuit at fresh gas ﬂow 
1 l.min-1  oxygen (a), mimicking mechanically ventilated patient (end-tidal volume 500 ml, 15 breaths. 
min-1, inhaled:exhaled phase time ratio 1:2) (b), mimicking spontaneously breathing patient (end-tidal volume 600 ml, 12 
breaths.min-1, inhaled:exhaled phase time ratio 1:2) (c). Target sevoﬂurane concentration 8% v/v for 10 min (a). Target 
sevoﬂurane concentration 2% v/v for 60 min (b and c). Also shown, sevoﬂurane concentration equilibration on start-up (d). 
Data shown are an average over three runs. Error bars indicate SD. 
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Figure 10 Sevoﬂurane output of the anaesthetic delivery device at 20 °C, target output 0.5%, 1.0% and 1.5% v/v 
sevoﬂurane. Mimicking spontaneously breathing patients: fresh gas ﬂow 6 l.min-1  oxygen, end-tidal volume 500 ml, 
12 breaths.min-1, inhaled: exhaled phase time ratio 1:2 with Magill breathing circuit (a), and used in draw-over 
mode (b). Data shown are an average over three runs. Error bars indicate SD. 
  
 
safe use of a vapouriser to provide anaesthesia or seda- 
tion in contexts that are currently impracticable. 
As  with  all  anaesthesia methods,  and  in  accor- 
dance  with  recommendations  of  the  Association of 
 
Anaesthetists of  Great  Britain  and  Ireland  (AAGBI) 
that the concentration of volatile anaesthetic agents is 
routinely monitored from induction through mainte- 
nance  and  into  recovery [12], the  routine  use of an 
  
 
appropriate   analyser  would  be  required   with   this 
device in order to conﬁrm that the correct concentra- 
tion of anaesthetic is delivered. 
The device was designed with the aim of provid- 
ing anaesthesia to a ‘standard’  patient  for up  to 1 h, 
although in practice it was possible to extend this to 
90 min.  If used with paediatric patients, the  concen- 
tration  of anaesthetic required  would be greater, but 
this would be compensated for by the  lower ﬂow of 
fresh gas. It is envisaged that  the ﬁnal design for the 
device will include a cartridge system containing the 
emulsion,  so  that  for  surgery  requiring  anaesthesia 
for longer than  90 min,  the  cartridge containing  the 
anaesthetic can be replaced easily in  only a few sec- 
onds.  Different  formulations  could  be  used  to  pro- 
vide anaesthesia or to limit the available vapour 
concentration  to safely provide lower sedative con- 
centrations. 
In conclusion, a novel method for delivering vola- 
tile anaesthetic agents to patients from an emulsion 
contained in a delivery device is described. In combi- 
nation with appropriate monitoring, the device is suit- 
able  for  use  using  either   a  circle  or   semi-closed 
breathing system, over a range of ﬂows and tempera- 
tures. The ﬂexibility to provide low, constant concen- 
trations of anaesthetic suggests that the formulation is 
also  suitable  for  delivery of  volatile sedation.  Once 
fully developed, this device may have a place in situa- 
tions, where access to complex anaesthetic equipment 
is difﬁcult or impractical. The next stage will be to 
demonstrate   that   the  unique  emulsion  formulation 
does not  produce any unexpected effects on lung tis- 
sue, which is required before we can conduct clinical 
trials and apply for CE marking. 
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